Li Kang Biomedical Co., Ltd. (TPEX:6242)
Taiwan · Delayed Price · Currency is TWD 38.15
0.00 (0.00%)
Jun 15, 2026, 1:30 PM CST
Li Kang Biomedical Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,213 | 1,248 | 1,364 | 1,563 | 1,315 | 872 | |
Market Cap Growth | -7.06% | -8.51% | -12.69% | 18.87% | 50.69% | 5.93% |
Enterprise Value | 1,157 | 1,187 | 996 | 1,413 | 1,116 | 788 |
Last Close Price | 38.15 | 39.25 | 40.91 | 52.92 | 41.96 | 27.00 |
PE Ratio | 15.66 | 14.89 | 17.72 | 14.08 | 11.73 | 16.96 |
PS Ratio | 2.11 | 2.12 | 2.41 | 2.48 | 1.92 | 2.26 |
PB Ratio | 1.38 | 1.43 | 1.60 | 2.48 | 2.31 | 1.77 |
P/TBV Ratio | 1.38 | 1.43 | 1.60 | 2.49 | 2.31 | 1.77 |
P/FCF Ratio | - | - | 518.62 | 16.72 | 8.42 | 15.53 |
P/OCF Ratio | 17.20 | 13.55 | 20.87 | 16.15 | 8.36 | 14.43 |
EV/Sales Ratio | 2.01 | 2.02 | 1.76 | 2.25 | 1.63 | 2.04 |
EV/EBITDA Ratio | 11.67 | 11.09 | 9.92 | 9.88 | 7.52 | 11.23 |
EV/EBIT Ratio | 12.64 | 12.08 | 11.06 | 10.59 | 8.12 | 13.76 |
EV/FCF Ratio | - | - | 378.39 | 15.12 | 7.15 | 14.02 |
Debt / Equity Ratio | 0.14 | 0.14 | 0.11 | 0.14 | - | 0.07 |
Debt / EBITDA Ratio | 1.27 | 1.18 | 0.90 | 0.63 | - | 0.48 |
Debt / FCF Ratio | - | - | 34.94 | 0.97 | - | 0.60 |
Net Debt / Equity Ratio | -0.06 | -0.07 | -0.42 | -0.33 | -0.46 | -0.29 |
Net Debt / EBITDA Ratio | -0.57 | -0.60 | -3.61 | -1.47 | -1.78 | -2.03 |
Net Debt / FCF Ratio | 0.23 | 0.27 | -137.77 | -2.25 | -1.69 | -2.53 |
Asset Turnover | 0.53 | 0.55 | 0.61 | 0.83 | 1.05 | 0.61 |
Inventory Turnover | 3.74 | 4.20 | 4.14 | 5.40 | 9.13 | 3.75 |
Quick Ratio | 1.21 | 1.18 | 4.93 | 2.83 | 2.31 | 2.08 |
Current Ratio | 1.57 | 1.50 | 5.45 | 3.24 | 2.61 | 2.45 |
Return on Equity (ROE) | 8.86% | 9.71% | 10.37% | 18.50% | 21.11% | 10.28% |
Return on Assets (ROA) | 5.24% | 5.77% | 6.04% | 11.00% | 13.16% | 5.67% |
Return on Invested Capital (ROIC) | 9.04% | 12.18% | 15.31% | 26.03% | 33.32% | 13.67% |
Return on Capital Employed (ROCE) | 9.80% | 10.60% | 9.60% | 18.60% | 24.10% | 10.80% |
Earnings Yield | 6.39% | 6.71% | 5.64% | 7.10% | 8.53% | 5.90% |
FCF Yield | -20.09% | -19.00% | 0.19% | 5.98% | 11.87% | 6.44% |
Dividend Yield | 5.24% | 5.10% | 4.89% | 4.72% | 4.15% | 4.60% |
Payout Ratio | 82.01% | 75.89% | 103.24% | 42.00% | 29.71% | 120.85% |
Buyback Yield / Dilution | 0.47% | -2.50% | -15.70% | - | -0.10% | 0.23% |
Total Shareholder Return | 5.72% | 2.60% | -10.81% | 4.72% | 4.04% | 4.83% |